Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biotech deals
Biotech
Gone are the bear days for biotech? William Blair thinks so
The analyst’s optimism is rooted in continued M&A activity, with 2025's biopharma deal volume the highest recorded in the last decade.
Gabrielle Masson
Dec 12, 2025 10:55am
Cycle Pharma scoops up beleaguered rare disease biotech
Dec 12, 2025 9:55am
Formation Bio makes $605M play for Lynk's TYK2 inhibitor
Dec 10, 2025 10:27am
Royalty's $275M financing deal for Denali drug awaiting FDA nod
Dec 4, 2025 10:20am
Akebia promises $12M for Q32’s rare kidney disease candidate
Dec 1, 2025 9:45pm
Gilead hatches $400M biobucks deal for Sprint's TREX1 program
Nov 24, 2025 12:20pm
